Takeda Announces U.S. FDA Breakthrough Therapy Designation For Mobocertinib(TAK-788) For The Treatment Of NSCLC Patients With EGFR Exon 20 Insertion Mutations
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation ...
